This seminar was fortunate to have invited Dr. Zhang Wei as the guest speaker. Dr. Zhang Wei, graduated from Tsinghua University, obtained a master's degree in intellectual property from the Federal Institute of Technology in Zurich, Switzerland, and a Ph.D. in molecular biology from the University of Zurich, Switzerland. Dr. Zhang from his own work. From the beginning of the experience, we will share and discuss the "the essence of patents, the special significance of patents for pharmaceutical companies, and the merits of patents", and expound the knowledge from the perspectives of heavy drug protection, patent strategy, patent disputes and patent challenges. The whole life cycle management and layout of property rights, combined with specific projects from the early research and development research phase, product development phase to the patent after the product launch, the case study.

 

During the meeting, the participants exchanged their understanding and doubts about patent protection, patent issues encountered in the R&D process of their own enterprises, patent application issues, patent infringement judgment and defense, and what is the entry point for patent challenges, evading patents, etc. The problem, Dr. Zhang combined with the actual case analysis, in-depth discussion of exchanges, so that everyone's understanding of patents is more profound and benefited a lot.

 

Nowadays, intellectual property protection is increasingly valued by enterprises, especially in technology-intensive enterprises. Intellectual property rights are powerful weapons that determine the strategic development of enterprises. Hope Medicine is a science and technology enterprise with technology research and development as its core. New technologies, new methods and new ideas emerge one after another. How to protect your own intellectual property rights and protect the value of enterprises determines the lifeline of enterprise development. At the same time, generic drug research and development is one of the main business of Hope Pharmaceutical. The domestic clinically urgently needed products are subject to foreign patent protection. During the patent protection period, other enterprises cannot copy it. How to successfully challenge the patent breakthrough technical barriers of the original research, for the Chinese people as soon as possible The use of clinically urgently needed drugs is of great significance.

 

[Introduction to TipLab]

 

TipLab is China's cutting-edge research consulting firm focused on strategic asset management. Based on in-depth research on innovative and active technology areas, especially cutting-edge technologies such as medical health, life sciences, and artificial intelligence, TipLab helps technology-driven companies gain access through strategic knowledge asset management and unique computer-aided systems. And maintain a competitive advantage in business.

 

【Introduction to Hope Medicine】

 

Beijing Hope Pharmaceutical Technology Co., Ltd. (stock short name: Hope, stock code: 836438) was founded in 2005 in Beijing Economic and Technological Development Zone. It is a high-tech enterprise with a focus on chemical drug research and development. The company is mainly engaged in research and development, production, sales, technology transfer and technical services of chemical raw materials, pharmaceutical intermediates and pharmaceutical preparations. It owns two wholly-owned subsidiaries of Beijing Haimeitong and Beijing Haimeiyuan.

 

Hope Medicine has more than 4,000 square meters of laboratories, nearly 200 people's research and development team, 32% of masters and above, equipped with conventional instruments and high-end equipments such as chemical synthesis, preparation, analysis, etc., from small to pilot scale, complete range, Provides adequate protection for high quality research and development. Research and development work has been carried out in various fields such as anti-tumor, depression, cardiovascular and cerebrovascular, digestive system, and respiratory medicine, and many research results have been obtained.

 

[Introduction to Tongchuang Weiye]

 

Tongchuang Weiye is China's first batch of professional private equity investment companies with 17 years of asset management experience, and its asset management scale ranks among the top in the industry. The company's long-term focus on venture capital investment is a domestic brand professional investment institution with leading position, long operating time and excellent return.